生物
转移
癌症研究
化疗
癌症
卵巢癌
原发性肿瘤
日历年61
细胞
肿瘤科
内科学
医学
受体
生长因子
遗传学
CTGF公司
作者
Tongtong Kan,Shupeng Zhang,Shengtao Zhou,Zhang Ya,Yun Zhao,Ying-Hua Gao,Tao Zhang,Feng Gao,Xin Wang,Linjie Zhao,Mengsu Yang
出处
期刊:Oncogene
[Springer Nature]
日期:2022-01-07
卷期号:41 (6): 895-906
被引量:37
标识
DOI:10.1038/s41388-021-02139-z
摘要
Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61+ "stress" subpopulation was identified as the relapse-initiators. Furthermore, a subpopulation of RGS5+ cancer-associated fibroblasts (CAFs) was found to strongly support tumor metastasis. The combined CYR61/RGS5 expression scores significantly correlated with the relapse-free-survival of EOC patients and can be used as predictors of EOC recurrence. Our study provides insights into the mechanism of EOC recurrence and presents CYR61+ relapse-initiating cells as potential therapeutic targets to prevent EOC relapse.
科研通智能强力驱动
Strongly Powered by AbleSci AI